Thursday, November 19, 2009

Sucampo Receives Marketing Authorization for Amitiza in Switzerland for Treatment of Chronic Idiopathic Constipation

Nov 19, 2009 - Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

The details can be read here.

No comments: